The Molecular Basis of Predicting Atherosclerotic Cardiovascular Disease Risk.
Nayor M, Brown KJ, Vasan RS.
Circ Res. 2021 Jan 22;128(2):287-303. doi: 10.1161/CIRCRESAHA.120.315890. Epub 2021 Jan 21.
Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association.
Reyes-Soffer G, Ginsberg HN, Berglund L, Duell PB, Heffron SP, Kamstrup PR, Lloyd-Jones DM, Marcovina SM, Yeang C, Koschinsky ML; American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; and Council on Peripheral Vascular Disease.
Arterioscler Thromb Vasc Biol. 2022 Jan;42(1):e48-e60. doi: 10.1161/ATV.0000000000000147. Epub 2021 Oct 14.
Trained immunity in atherosclerotic cardiovascular disease.
Riksen NP, Bekkering S, Mulder WJM, Netea MG.
Nat Rev Cardiol. 2023 Dec;20(12):799-811. doi: 10.1038/s41569-023-00894-y. Epub 2023 Jun 15.
Low-dose aspirin for the prevention of atherosclerotic cardiovascular disease.
Patrono C.
Eur Heart J. 2024 Jul 12;45(27):2362-2376. doi: 10.1093/eurheartj/ehae324.
Colchicine in atherosclerotic cardiovascular disease.
Tucker B, Goonetilleke N, Patel S, Keech A.
Heart. 2024 Apr 15;110(9):618-625. doi: 10.1136/heartjnl-2023-323177.
The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk.
Sandesara PB, Virani SS, Fazio S, Shapiro MD.
Endocr Rev. 2019 Apr 1;40(2):537-557. doi: 10.1210/er.2018-00184.
Lp(a) (Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular Disease: New Insights From a Large National Biobank.
Patel AP, Wang (汪敏先) M, Pirruccello JP, Ellinor PT, Ng K, Kathiresan S, Khera AV.
Arterioscler Thromb Vasc Biol. 2021 Jan;41(1):465-474. doi: 10.1161/ATVBAHA.120.315291. Epub 2020 Oct 29.
Autoimmune diseases and atherosclerotic cardiovascular disease.
Porsch F, Binder CJ.
Nat Rev Cardiol. 2024 Nov;21(11):780-807. doi: 10.1038/s41569-024-01045-7. Epub 2024 Jun 27.
Atherosclerotic Cardiovascular Disease in Women: Providing Protection With Lipid-altering Agents.
Hiles M, Simmons A, Hilleman D, Gibson CA, Backes JM.
Clin Ther. 2023 Nov;45(11):1127-1136. doi: 10.1016/j.clinthera.2023.08.021. Epub 2023 Sep 26.
Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association.
Duell PB, Welty FK, Miller M, Chait A, Hammond G, Ahmad Z, Cohen DE, Horton JD, Pressman GS, Toth PP; American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Hypertension; Council on the Kidney in Cardiovascular Disease; Council on Lifestyle and Cardiometabolic Health; and Council on Peripheral Vascular Disease.
Arterioscler Thromb Vasc Biol. 2022 Jun;42(6):e168-e185. doi: 10.1161/ATV.0000000000000153. Epub 2022 Apr 14.
